Table 1.
Location (City, Country) |
Study Period |
No. of Households |
No. of Subjects |
Recruitment Strategyb |
Multiple Index |
Index case ascertainment |
Primary Outcome |
All contacts |
Primary SIR, % | Secondary Outcome(s) |
Secondary SIR(s), % |
Follow-up duration of households |
Serial interval (days) |
Mean Household size | Serology Collected |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calatayud et al 201018 | London, UK | Apr 09 – May 09 | n/a | 47 | Cohort | N | RT-PCR | RT-PCR | N | 17% | n/a | n/a | n/a | n/a | n/a | N |
Carcione et al 201119 | Western Australia | May 09 – Aug 09 | 595 | 2184 | Case ascertained | N | RT-PCR | RT- PCR/FARI combined | N | 20% | n/a | n/a | 8 | Mean: 3.2, Median: 3 | 3.8 | N |
Cauchemez et al 200920 | USA | Apr 09 – May 09 | 216 | 816 | Case ascertained | N | RT-PCR | ARI | N | 13% | FARI | 10% | 7 | Mean: 2.9 | n/a | N |
Chang et al 201121 | Taiwan | Aug 09 – Nov 09 | 87 | 223 | Case ascertained | N | RT-PCR + serology | RT-PCR + serology | Y | 27% | n/a | n/a | 7 | Mean: 2,.3 | n/a | Y |
Cowling et al 201022 | Hong Kong | Jul 09 – Aug 09 | 105 | 309 | Case ascertained | N | RT-PCR | RT-PCR | Y | 7.8% | ARI, FARI | 26%, 6.1% | 7 | Mean: 3.2 | n/a | Y |
Doyle et al 201123 | USA | Jun 09 | 53 | 163 | Case ascertained | Y | FARI | FARI | N | 3.4% | n/a | n/a | n/a | Mean: 3 | n/a | N |
France et al 201024 | New York, USA | Apr 09 | 322 | 1042 | Case ascertained | N | RT- PCR/FARI | FARI | N | 11% | n/a | n/a | n/a | Median: 3 | 4.1 | N |
Goldstein et al 201025 | Milwaukee, USA | Apr 09 – Jun 09 | 135 | 546 | Case ascertained | N | RT-PCR | FARI | N | 13% | n/a | n/a | 7 | Mean: 3.32 | n/a | N |
Komiya et al 201027 | Osaka, Japan | May 09 | 124 | 503 | Case ascertained | N | RT-PCR | RT-PCR | N | 3.7% | n/a | n/a | n/a | Median: 3 | 3.1 | N |
Leung et al 201128 | Hong Kong | Jun 09 | 65 | 270 | Case ascertained | N | RT-PCR | RT-PCR | N | 5.9% | n/a | n/a | 14 | Mean: 2.8 | n/a | N |
Looker et al 201029 | Victoria, Australia | May 09 – Aug 09 | 132 | 483 | Case ascertained | N | RT-PCR | FARI | N | 33% | n/a | n/a | n/a | n/a | 3.9 | N |
Loustalot et al 201130 | Texas, USA | May 09 | 668 | 640 | Cohort | N | FARI | FARI | N | 3.7% | n/a | n/a | 10 | n/a | n/a | N |
Mohamed et al 201131 | Riyadh, Saudi Arabia | Sep 09 – Oct 09 | 69 | 432 | Case ascertained | N | RT-PCR | FARI | N | 17% | n/a | n/a | 12 | n/a | n/a | N |
Morgan et al 201032 | Texas, USA | Apr 09 – May 09 | 77 | 349 | Case ascertained | N | RT-PCR/FARI | RT-PCR | N | 4.2% | ARI, FARI | 13%, 9.3% | 9 | Median: 4 | n/a | N |
Nishiura et al 201133 | Japan | May 09 – Feb 10 | 1547 | 6156 | Case ascertained | N | RT- PCR/FARI | FARI | N | 11% | n/a | n/a | 7 | Mean: 3.1, Median: 3 | n/a | N |
Odaira et al 200934 | Kobe, Japan | May 09 – Jun 09 | 97 | 400 | Case ascertained | N | RT-PCR | RT-PCR | N | 4.1% | ARI | 4.8% | 8 | Mean: 2.9, Median: 3 | n/a | N |
Papenburg et al 201035 | Quebec, Canada | May 09 – Jul 09 | 42 | 162 | Case ascertained | Y | RT-PCR | RT-PCR + Serology | Y | 45% | RT- PCR, ARI, FARI | 38%, 51%, 29% | 11 | Mean: 3.9, Median: 3 | 3.8 | Y |
Pebody et al 201136 | UK | Apr 09 – Jun 09 | 259 | 1046 | Case ascertained | Y | RT-PCR | RT-PCR | N | 8.3% | ARI, FARI | 16%,11% | 7 | n/a | 4.3 | N |
Pedroni et al 201037 | Chile | Jun 09 | 57 | 302 | Case ascertained | N | RT-PCR | FARI | N | 37% | n/a | n/a | 14 | Mean: 3.6, Median: 3 | 3.3 | N |
Savage et al 201138 | Ontario, Canada | Apr 09 – Jun 09 | 87 | 353 | Case ascertained | N | RT-PCR | ARI | N | 20% | FARI | 10% | 14 | Median: 3 | n/a | N |
Sikora et al 201039 | Alberta, Canada | Apr 09 – Jun 09 | 87 | 349 | Case ascertained | N | RT-PCR | FARI | N | 30% | n/a | n/a | 14 | n/a | 4.0 | N |
Simmerman et al 201140 | Bangkok, Thailand | Apr 09 – Aug 09 | 348 | 1233 | Case ascertained | N | RT-PCR | RT-PCR | Y | 21% | FARI | 14% | 7 | Mean: 3.32, Median: 2.94 | n/a | Y |
Suess et al 201041 | Germany | Apr 09 – Aug 09 | 36 | 119 | Case ascertained | N | RT-PCR | RT-PCR | Y | 18% | n/a | n/a | 8 | Mean: 2.6, Median: 3 | n/a | N |
Sugimoto et al 201142 | Washington, USA | May 09 – Jun 09 | 41 | 178 | Cohort | Y | RT- PCR/FARI | FARI | N | 5.9% | n/a | n/a | 7 | n/a | n/a | N |
van Boven et al 201043 | Netherlands | Apr 09 – Jun 09 | 47 | 156 | Case ascertained | N | RT-PCR | RT-PCR | N | 8.3% | n/a | n/a | 7 | n/a | n/a | N |
van Gemert et al 201144 | Victora, Australia | May 09 – Jun 09 | 36 | 167 | Retrospective cross- sectional | N | RT-PCR | FARI | N | 15% | n/a | n/a | 9 | Median: 2 | 3.1 | N |
One study (Jackson et al26) was not included in this table because it provided only supplementary serologic data of a previous study (France et al24). Data are included in the main text.
Case ascertained means that index cases were identified through symptom screening or laboratory confirmation; Cohort, index cases were identified from specific populations (e.g. camps, schools, etc) and households without index cases were also followed up
Studies in which it would have been possible for more than one person in a household to be identified as index case (i.e. identification of potential co-primary cases).
RT-PCR indicates respiratory specimen positive for influenza by reverse transcription polymerase chain reaction; ARI, acute respiratory illness; FARI, febrile acute respiratory illness; primary SIR, secondary infection risk based on primary outcome; secondary SIR, secondary infection risk based on secondary outcome; Y, yes; N, no; n/a: not applicable.